Share Name Share Symbol Market Type Share ISIN Share Description
Napo Pharm.Regs LSE:NAPL London Ordinary Share USU629901039 COM USD0.0001 REGS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 0.35p 0.00p 0.00p - - - 0.00 05:00:11
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0.16

Napo Pharm.Regs (NAPL) Latest News

Real-Time news about Napo Pharm.Regs (London Stock Exchange): 0 recent articles
More Napo Pharm.Regs News
Napo Pharm.Regs Takeover Rumours

Napo Pharm.Regs (NAPL) Share Charts

1 Year Napo Pharm.Regs Chart

1 Year Napo Pharm.Regs Chart

1 Month Napo Pharm.Regs Chart

1 Month Napo Pharm.Regs Chart

Intraday Napo Pharm.Regs Chart

Intraday Napo Pharm.Regs Chart

Napo Pharm.Regs (NAPL) Discussions and Chat

Napo Pharm.Regs Forums and Chat

Date Time Title Posts
25/9/200810:37Napo with Charts & News156.00
17/4/200815:46Napo Pharmaceuticals10.00

Add a New Thread

Napo Pharm.Regs (NAPL) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Napo Pharm.Regs trades in real-time

Napo Pharm.Regs (NAPL) Top Chat Posts

DateSubject
08/5/2008
09:52
monis: 21 April 2008 Sir William Young, Chairman of the Board of Napo commented: "While Napo needs to bring in funds from corporate partnering and other activities in order to complete its Phase 3 trial, the board feels the recent stock price drop dramatically undervalues the company." Lisa A. Conte CEO of Napo Pharmaceuticals, Inc. commented: "It is my firm belief that, the fall in the Company's share price places an unrealistic value on Napo and disregards the recently announced trial results. The statistically significant results on crofelemer in the treatment of acute infectious diarrhoea have infused our on-going corporate partner and grant discussions with the opportunity to represent a potential dual indication approach to filings for regulatory approvals for crofelemer next year-chronic diarrhoea in people living with HIV/AIDS and acute infectious diarrhoea. This approach may potentially increase the likelihood of regulatory approval for at least one indication of crofelemer, it may also expand the available patient populations that might benefit from crofelemer, as well as increasing the target market size."
08/5/2008
08:58
monis: Up again. Share awards seem to me to state that directors don't get the shares unless the share price reaches $3.50 that is about a 1 pound seventy share price. So huge potential upside still. Of cause DYOR. It now just 9p!
29/4/2008
15:13
monis: From recent update. Make of it what you will. ...Management have plans to raise additional funds, which include: the out-license of certain rights to crofelemer including the indications of CRO-HIV, CRO-IBS,CRO-ID and CRO-PED in the United States and other western territories; as well as certain rights to NP-500, in exchange for a licensing fee(s)... ...Sir William Young, Chairman of the Board of Napo commented: "While Napo needs to bring in funds from corporate partnering and other activities in order to complete its Phase 3 trial, the board feels the recent stock price drop dramatically undervalues the company." ... Lisa A. Conte CEO of Napo Pharmaceuticals, Inc. commented: "It is my firm belief that, the fall in the Company's share price places an unrealistic value on Napo and disregards the recently announced trial results. Of cause DYOR.
23/4/2008
14:11
monis: From recent update. Make of it what you will. ...Management have plans to raise additional funds, which include: the out-license of certain rights to crofelemer including the indications of CRO-HIV, CRO-IBS,CRO-ID and CRO-PED in the United States and other western territories; as well as certain rights to NP-500, in exchange for a licensing fee(s)... ...Sir William Young, Chairman of the Board of Napo commented: "While Napo needs to bring in funds from corporate partnering and other activities in order to complete its Phase 3 trial, the board feels the recent stock price drop dramatically undervalues the company." ... Lisa A. Conte CEO of Napo Pharmaceuticals, Inc. commented: "It is my firm belief that, the fall in the Company's share price places an unrealistic value on Napo and disregards the recently announced trial results. Of cause DYOR.
Napo Pharm.Regs share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170323 12:14:49